{"id":55042,"date":"2026-01-22T01:56:06","date_gmt":"2026-01-21T17:56:06","guid":{"rendered":"https:\/\/flcube.com\/?p=55042"},"modified":"2026-01-22T01:56:07","modified_gmt":"2026-01-21T17:56:07","slug":"shanghai-pharmas-inkt-cell-therapy-b023-gets-nmpa-nod-for-advanced-solid-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55042","title":{"rendered":"Shanghai Pharma\u2019s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors"},"content":{"rendered":"\n<p><strong>Shanghai Pharmaceuticals Holding Co., Ltd<\/strong> (SPH, <a href=\"https:\/\/www.google.com\/finance\/quote\/2607:HKG\">HKG: 2607<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/601607:SHA\">SHA: 601607<\/a>) announced that its <strong>B023 cell injection<\/strong>, an <strong>allogeneic invariant natural killer T (iNKT) cell therapy<\/strong>, has been approved by China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> to enter clinical trials for <strong>locally advanced or metastatic solid tumors<\/strong> that are inoperable, have failed standard therapy, and lack effective treatment options.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Shanghai Pharmaceuticals Holding Co., Ltd (601607.SH)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>B023 cell injection (iNKT cell therapy)<\/td><\/tr><tr><td><strong>Application<\/strong><\/td><td>Investigational New Drug (IND)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Locally advanced or metastatic solid tumors (inoperable, post\u2011standard therapy failure)<\/td><\/tr><tr><td><strong>Core Technology<\/strong><\/td><td>Allogeneic invariant natural killer T (iNKT) cells<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>16\u202fJan\u202f2026<\/td><\/tr><tr><td><strong>Innovation<\/strong><\/td><td>First iNKT\u2011based universal (\u201coff\u2011the\u2011shelf\u201d) cell therapy for solid tumors in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cell Type:<\/strong> <strong>Invariant NKT (iNKT) cells<\/strong> \u2013 non\u2011classical T cells expressing invariant TCR (V\u03b124\u2011J\u03b118\/V\u03b211)<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Recognizes <strong>lipid antigens<\/strong> presented by <strong>CD1d<\/strong> (non\u2011polymorphic MHC\u2011class I\u2011like molecule) on tumor cells<\/li>\n<\/ul>\n\n\n\n<p><strong>Key Advantages:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Universal (Off\u2011the\u2011Shelf):<\/strong> CD1d non\u2011polymorphism enables <strong>allogeneic administration<\/strong> without <strong>graft\u2011vs\u2011host disease (GvHD)<\/strong><\/li>\n\n\n\n<li><strong>Dual Function:<\/strong> Direct <strong>cytotoxicity<\/strong> via CD1d\u2011targeting + <strong>immunomodulation<\/strong> via cytokine secretion (IFN\u2011\u03b3, IL\u20114)<\/li>\n\n\n\n<li><strong>Manufacturing:<\/strong> Scalable <strong>cGMP iNKT expansion<\/strong> from healthy donor peripheral blood<\/li>\n\n\n\n<li><strong>Safety:<\/strong> Lower risk of <strong>cytokine release syndrome<\/strong> vs. CAR\u2011T due to <strong>innate\u2011like regulation<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-competitive-landscape\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>China Solid Tumor Market<\/th><th>iNKT Cell Therapy Market<\/th><\/tr><\/thead><tbody><tr><td><strong>Advanced\/Metastatic Solid Tumor Patients (2026E)<\/strong><\/td><td>1.8\u202fmillion<\/td><td>\u2013<\/td><\/tr><tr><td><strong>Failed Standard Therapy<\/strong><\/td><td>540,000<\/td><td>\u2013<\/td><\/tr><tr><td><strong>Cell Therapy Addressable<\/strong><\/td><td>180,000<\/td><td>\u2013<\/td><\/tr><tr><td><strong>iNKT Therapy Penetration<\/strong><\/td><td>0%<\/td><td>0%<\/td><\/tr><tr><td><strong>Market Value (2030E)<\/strong><\/td><td>\u00a545\u202fbillion<\/td><td>\u00a58.5\u202fbillion<\/td><\/tr><tr><td><strong>B023 Peak Revenue (2032E)<\/strong><\/td><td>\u00a52.8\u202fbillion<\/td><td>\u2013<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Key Competitors:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CAR\u2011T:<\/strong> <strong>No approved CAR\u2011T<\/strong> for solid tumors; high toxicity (CRS, neurotoxicity)<\/li>\n\n\n\n<li><strong>TIL Therapy:<\/strong> <strong>Iovance<\/strong> (US) \u2013 autologous, manufacturing complexity; limited China presence<\/li>\n\n\n\n<li><strong>iNKT Platforms:<\/strong> <strong>Agenus<\/strong> (US, pre\u2011clinical), <strong>NKT Therapeutics<\/strong> (US, Phase\u202fI) \u2013 <strong>no competitors in late\u2011stage development<\/strong><\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> B023\u2019s <strong>off\u2011the\u2011shelf allogeneic approach<\/strong> avoids <strong>GvHD<\/strong>, <strong>reduces cost by 60\u201170%<\/strong> vs. autologous CAR\u2011T<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning-amp-next-steps\">Strategic Positioning &amp; Next Steps<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Manufacturing:<\/strong> Shanghai Pharma\u2019s <strong>Shanghai biologics facility<\/strong> (capacity 20,000\u202fL) will produce B023 for clinical trials; <strong>scale\u2011up to 50,000\u202fL<\/strong> by 2028<\/li>\n\n\n\n<li><strong>Clinical Development:<\/strong> <strong>Phase\u202fI\/II dose\u2011escalation<\/strong> in <strong>NSCLC, gastric, and triple\u2011negative breast cancer<\/strong> planned <strong>Q2\u202f2026<\/strong>; <strong>conditional approval pathway<\/strong> via <strong>BTD<\/strong> possible<\/li>\n\n\n\n<li><strong>Regulatory Path:<\/strong> <strong>First iNKT cell therapy<\/strong> in China; eligible for <strong>priority review<\/strong> and <strong>accelerated approval<\/strong><\/li>\n\n\n\n<li><strong>Commercialization:<\/strong> Shanghai Pharma\u2019s <strong>12,000\u2011hospital network<\/strong> and 3,000\u2011person sales force can rapidly commercialize upon approval<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, regulatory pathways, and commercial projections for B023. Actual results may differ due to clinical trial outcomes, competitive dynamics, and manufacturing scale\u2011up challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/601607_20260121_1Y8J.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 601607_20260121_1Y8J.\"><\/object><a id=\"wp-block-file--media-9dec2347-bcd1-4ac1-b2d6-57cba1a155d7\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/601607_20260121_1Y8J.pdf\">601607_20260121_1Y8J<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/601607_20260121_1Y8J.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-9dec2347-bcd1-4ac1-b2d6-57cba1a155d7\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Pharmaceuticals Holding Co., Ltd (SPH, HKG: 2607, SHA: 601607) announced that its B023 cell&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,77,62,890,891,196,691],"class_list":["post-55042","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-cell-therapy","tag-clinical-trial-approval-initiation","tag-hkg-2607","tag-sha-601607","tag-shanghai-pharmaceuticals","tag-sph"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shanghai Pharma\u2019s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Pharmaceuticals Holding Co., Ltd (SPH, HKG: 2607, SHA: 601607) announced that its B023 cell injection, an allogeneic invariant natural killer T (iNKT) cell therapy, has been approved by China\u2019s National Medical Products Administration (NMPA) to enter clinical trials for locally advanced or metastatic solid tumors that are inoperable, have failed standard therapy, and lack effective treatment options.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55042\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shanghai Pharma\u2019s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors\" \/>\n<meta property=\"og:description\" content=\"Shanghai Pharmaceuticals Holding Co., Ltd (SPH, HKG: 2607, SHA: 601607) announced that its B023 cell injection, an allogeneic invariant natural killer T (iNKT) cell therapy, has been approved by China\u2019s National Medical Products Administration (NMPA) to enter clinical trials for locally advanced or metastatic solid tumors that are inoperable, have failed standard therapy, and lack effective treatment options.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55042\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-21T17:56:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-21T17:56:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55042#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55042\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shanghai Pharma\u2019s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors\",\"datePublished\":\"2026-01-21T17:56:06+00:00\",\"dateModified\":\"2026-01-21T17:56:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55042\"},\"wordCount\":454,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Cell-therapy\",\"Clinical trial approval \\\/ initiation\",\"HKG: 2607\",\"SHA: 601607\",\"Shanghai Pharmaceuticals\",\"SPH\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55042#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55042\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55042\",\"name\":\"Shanghai Pharma\u2019s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-21T17:56:06+00:00\",\"dateModified\":\"2026-01-21T17:56:07+00:00\",\"description\":\"Shanghai Pharmaceuticals Holding Co., Ltd (SPH, HKG: 2607, SHA: 601607) announced that its B023 cell injection, an allogeneic invariant natural killer T (iNKT) cell therapy, has been approved by China\u2019s National Medical Products Administration (NMPA) to enter clinical trials for locally advanced or metastatic solid tumors that are inoperable, have failed standard therapy, and lack effective treatment options.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55042#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55042\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55042#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shanghai Pharma\u2019s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shanghai Pharma\u2019s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Pharmaceuticals Holding Co., Ltd (SPH, HKG: 2607, SHA: 601607) announced that its B023 cell injection, an allogeneic invariant natural killer T (iNKT) cell therapy, has been approved by China\u2019s National Medical Products Administration (NMPA) to enter clinical trials for locally advanced or metastatic solid tumors that are inoperable, have failed standard therapy, and lack effective treatment options.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55042","og_locale":"en_US","og_type":"article","og_title":"Shanghai Pharma\u2019s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors","og_description":"Shanghai Pharmaceuticals Holding Co., Ltd (SPH, HKG: 2607, SHA: 601607) announced that its B023 cell injection, an allogeneic invariant natural killer T (iNKT) cell therapy, has been approved by China\u2019s National Medical Products Administration (NMPA) to enter clinical trials for locally advanced or metastatic solid tumors that are inoperable, have failed standard therapy, and lack effective treatment options.","og_url":"https:\/\/flcube.com\/?p=55042","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-21T17:56:06+00:00","article_modified_time":"2026-01-21T17:56:07+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55042#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55042"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shanghai Pharma\u2019s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors","datePublished":"2026-01-21T17:56:06+00:00","dateModified":"2026-01-21T17:56:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55042"},"wordCount":454,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Cell-therapy","Clinical trial approval \/ initiation","HKG: 2607","SHA: 601607","Shanghai Pharmaceuticals","SPH"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55042#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55042","url":"https:\/\/flcube.com\/?p=55042","name":"Shanghai Pharma\u2019s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-21T17:56:06+00:00","dateModified":"2026-01-21T17:56:07+00:00","description":"Shanghai Pharmaceuticals Holding Co., Ltd (SPH, HKG: 2607, SHA: 601607) announced that its B023 cell injection, an allogeneic invariant natural killer T (iNKT) cell therapy, has been approved by China\u2019s National Medical Products Administration (NMPA) to enter clinical trials for locally advanced or metastatic solid tumors that are inoperable, have failed standard therapy, and lack effective treatment options.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55042#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55042"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55042#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shanghai Pharma\u2019s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55042","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55042"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55042\/revisions"}],"predecessor-version":[{"id":55045,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55042\/revisions\/55045"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55042"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55042"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55042"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}